Luo Xuemei, Doherty Jim, Cappelleri Joseph C, Frush Karen
Duke University Health System, Durham, NC, USA.
Curr Med Res Opin. 2007 Nov;23(11):2607-15. doi: 10.1185/030079907x233250.
Pharmacoepidemiology is a discipline that applies epidemiological methodologies to the study of drug use, especially the safety of drug use in a large group of people. But this methodology has not been widely utilized to assess drug safety in pediatrics for children aged between 0 and 18 years.
(1) To describe current gaps in evaluating pediatric drug safety; (2) to use published examples demonstrating the value of pharmacoepidemiology in detecting and quantifying adverse drug events in pediatrics; (3) to review pharmacoepidemiological study designs, their strengths and limitations, and examples of their applications in the field of drug safety evaluation; and (4) to provide recommendations about selecting an appropriate study design and minimizing a major methodological limitation.
Only about 20% of approved drugs are licensed for pediatric use, and many prescription drugs are used as 'off label' or 'unlicensed' pediatric treatments. Among this small percentage of licensed pediatric drugs, pre-marketing trials may not adequately address all drug-related safety issues in pediatrics. Consequently, an important gap exists in pediatric drug safety evaluation. Pharmacoepidemiology offers a number of advantages in detecting and quantifying adverse drug events in pediatrics. Each pharmacoepidemiological study design has its own strengths and limitations in the evaluation of drug safety. An appropriate study design depends on the underlying research question being addressed. Confounding by indication, the most serious and challenge form of confounding in pharmacoepidemiological designs, could lead to misleading claims about the relationship between drug use and the development of potential adverse drug events, and should be adequately controlled.
Pharmacoepidemiology is a powerful methodology that offers many advantages to assess pediatric drug safety such as large sample size, long period of follow-up, and good generalizibility. But this methodology should be applied judiciously to maximize its potential.
药物流行病学是一门应用流行病学方法研究药物使用情况,尤其是一大群人用药安全性的学科。但这种方法尚未广泛用于评估0至18岁儿童的药物安全性。
(1)描述当前评估儿科药物安全性方面的差距;(2)列举已发表的实例,以证明药物流行病学在检测和量化儿科药物不良事件中的价值;(3)回顾药物流行病学研究设计、其优势和局限性,以及它们在药物安全性评估领域的应用实例;(4)就选择合适的研究设计和最大限度减少主要方法学局限性提供建议。
只有约20%的获批药物获得了儿科用药许可,许多处方药被用作“未标明适应证”或“未获许可”的儿科治疗药物。在这一小部分有儿科用药许可的药物中,上市前试验可能无法充分解决儿科中所有与药物相关的安全问题。因此,儿科药物安全性评估存在重要差距。药物流行病学在检测和量化儿科药物不良事件方面具有诸多优势。每种药物流行病学研究设计在评估药物安全性方面都有其自身的优势和局限性。合适的研究设计取决于所解决的潜在研究问题。适应证混杂是药物流行病学设计中最严重且具有挑战性的混杂形式,可能导致关于药物使用与潜在药物不良事件发生之间关系的误导性论断,应予以充分控制。
药物流行病学是一种强大的方法,在评估儿科药物安全性方面具有诸多优势,如样本量大、随访期长和良好的可推广性。但应明智地应用这种方法以最大限度发挥其潜力。